How effective is Selpercatinib?

Selpercatinib is a kinase inhibitor with higher specificity for RET tyrosine kinase receptors (RTKs) than other RTKs. Enhanced RET (rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors have been shown to be effective against RET-driven cancers, their lack of specificity is often associated with substantial toxicity. Serpatinib is a first-generation specific RET RTK inhibitor for the treatment of RET-driven cancers. For the treatment of adult patients with RET fusion-positive non-small cell lung cancer (NSCLC), RET mutant medullary thyroid carcinoma (MTC), RET fusion-positive thyroid cancer, and RET gene fusion locally advanced or metastatic solid tumors.